Nevada Sunrise Metals Corporation (TSXV:NEV)

Blueprint Medicines Income Statement

Financials in millions CAD. Fiscal year is October - September.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Sep 30, 2024	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021	Sep 30, 2020
Cost of Revenue	-	-	-	0	0	-
Gross Profit	-	-	-	-0	-0	-
Selling, General & Admin	0.35	0.4	0.59	0.54	0.42	0.36
Operating Expenses	0.49	0.94	2.46	1.31	2.09	0.38
Operating Income	-0.49	-0.94	-2.46	-1.32	-2.09	-0.38
Interest & Investment Income	0.01	0.01	-	-	-	-
Currency Exchange Gain (Loss)	-0	-0	0.01	0	-0	-0.01
Other Non Operating Income (Expenses)	-0.16	-0.24	-0.36	1.14	-0.11	-0.1
EBT Excluding Unusual Items	-0.65	-1.18	-2.81	-0.18	-2.2	-0.48
Gain (Loss) on Sale of Investments	-0.06	-0.05	-0.06	-0.18	0.03	-0.04
Gain (Loss) on Sale of Assets	0.63	0.63	0.14	0.77	0.07	-
Other Unusual Items	-	-	-	-	0.01	-0.01
Pretax Income	-0.07	-0.6	-2.73	0.42	-2.1	-0.53
Net Income	-0.07	-0.6	-2.73	0.42	-2.1	-0.53
Net Income to Common	-0.07	-0.6	-2.73	0.42	-2.1	-0.53
Shares Outstanding (Basic)	111	110	99	84	76	56
Shares Outstanding (Diluted)	111	110	99	85	76	56
Shares Change (YoY)	5.50%	10.38%	16.61%	11.37%	36.43%	14.26%
EPS (Basic)	-0.00	-0.01	-0.03	0.01	-0.03	-0.01
EPS (Diluted)	-0.00	-0.01	-0.03	0.01	-0.03	-0.01
Free Cash Flow	-0.81	-1.01	-2.6	-2.22	-1.91	-0.43
Free Cash Flow Per Share	-0.01	-0.01	-0.03	-0.03	-0.03	-0.01
EBITDA	-0.44	-0.89	-2.34	-	-	-0.21
D&A For EBITDA	0.06	0.05	0.12	-	-	0.16
EBIT	-0.49	-0.94	-2.46	-1.32	-2.09	-0.38

Updated Mar 2, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.